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Abstract
Rationale Although depression is the most common mood
disorder, only one third of patients are treated with success.
Finding new targets, new drugs, and also new drug intake way
are the main challenges in the depression field. Several years
ago, we identified a new target with the TWIK-related potas-
sium channel-1 (TREK-1) potassium channel, and more re-
cently, we have discovered a peptide of 17 amino acids with
antidepressant properties. This peptide, that we called spadin,
can be considered as a new concept in antidepressant drug
design. Spadin derives from a larger peptide resulting to a
posttranslational maturation of sortilin; consequently, spadin
can be considered as a natural molecule. Moreover, spadin
acts more rapidly than classical antidepressants and does not
induce side effects.
Objectives In this work, we sought analogs of spadin
displaying a better affinity on TREK-1 channels and an in-
creased action duration.
Methods Analogs were characterized by electrophysiology
measurements, by behavioral tests, and by their ability to
induce neurogenesis.
Results We identified two retro-inverso peptides that have
kept the antidepressant properties of spadin; particularly, they
increased the hippocampal neurogenesis after a 4-day treat-
ment. As spadin, these analogs did not induce side effects on
either pain, epilepsy processes, or at the cardiac level.
Conclusions Together, our results indicated that spadin retro-
inverso peptides could represent new potent antidepressant
drugs. As exemplified by spadin in the field of depression,
retro-inverso strategies could represent a useful technique for
developing new classes of drugs in a number of pathologies.
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Introduction
Depression is a devastating neuropsychiatric disorder and
affects approximately 20 % of the population. Depression is
predicted to be a major cause of morbidity worldwide in the
next 10 years and will induce an important economic burden
(Greenberg et al. 2003; Moussavi et al. 2007). Depression is a
multifactorial and multigenic disease characterized by many
symptoms like fatigue, anhedonia, pessimism, irritability,
sleep troubles, increased or decreased appetite, guiltiness,
and suicidal tendencies (Nestler et al. 2002). Sixty years
ago, antidepressant treatments have been revolutionized by
the discovery of tricyclic antidepressants and monoamine
oxidase inhibitors. Later, a second generation of antidepres-
sants was developed with the selective serotonin or
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norepinephrine selective reuptake inhibitors. Despite their
efficacy, around one third of patients remain unresponsive to
these drugs. Moreover, they display some adverse side effects
and have a long onset of action (Sicouri and Antzelevitch
2008). Consequently, it was necessary to develop new antide-
pressant molecules with new pharmacological targets.
We previously demonstrated that the inhibition of TREK-1
led to an antidepressant phenotype (Heurteaux et al. 2006b).
Our researches led to the identification of a specific inhibitor of
TREK-1 channel called spadin (Mazella et al. 2010). Spadin
resulted from modification of the sortilin receptor (Mazella
et al. 1998). Spadin is a 17 amino acid peptide which was
designed from a 44 amino acid peptide (called PE) released
by furin in the late Golgi apparatus during the posttranslational
maturation of the sortilin receptor (Munck Petersen et al. 1999).
Spadin is able to block the TREK-1 potassium channel current
and displays antidepressant effects in different behavioral tests
(Mazella et al. 2010). Additionally, like other antidepressant
drugs, spadin is able to increase neurogenesis and serotoniner-
gic transmission. More interestingly, unlike the most used
antidepressants, which need 21 days to be efficient, spadin
has a quicker onset of action since it is able to induce these
improvements only after a 4-day treatment (Mazella et al.
2010). In the two pore (K2P) potassium channel family, spadin
is specific for TREK-1 channels (Moha ou Maati et al. 2011b).
Moreover, the activation of TREK-1 channels was demonstrat-
ed to be beneficial in different functions such as general anes-
thesia, neuroprotection by the way of polyunsaturated fatty
acids, pain, ischemia, and epilepsy (Alloui et al. 2006;
Heurteaux et al. 2006a; Lauritzen et al. 2000; Noel et al.
2009). Nevertheless, blockade of TREK-1 channels by spadin
does not interfere with these functions. In other words, spadin is
devoid of side effects on TREK-1-controlled functions
(Moha ou Maati et al. 2011b). Importantly, spadin does not
induce any cardiac dysfunctions, and both systolic pressure
and pulses are not affected by a 3-week spadin treatment.
Additionally, spadin is unable to block the two most important
repolarizing currents in the heart (IKR, IKS) (Moha ou Maati
et al. 2011b). Taken together, these properties are strong
evidences for considering spadin as an antidepressant drug
of a new generation.
With the aim to identify new analogs displaying a better
efficacy than spadin, we synthesized different portions of
human sortilin either in natural L-configuration or retro-
inverso configuration. This approach consists in synthesizing
peptides in which not only the chirality of amino acid is
inverted by replacing all L-amino acids by D-amino acids but
also the amino acid sequence is reversed (Bonny et al. 2001;
Chorev and Goodman 1995). In such a way, the side chains of
amino acids are in a similar position to that of the native
peptide (Bonny et al. 2001; Chorev and Goodman 1995;
Van Regenmortel and Muller 1998). Very often, retro-
inverso peptide properties are the same or close, sometimes
better, than the parent L-peptides and, overall, retro-inverso
peptides are more resistant to proteolysis (Taylor et al. 2010;
Weeden et al. 2011).
We first screened 12 spadin analogs for their ability to
block TREK-1 channel activity. The two most efficient were
retained for further studies using behavioral tests and mea-
surements of their effects on neurogenesis. Because the
TREK-1 channel deletion was shown to be deleterious for
epilepsy or pain (Alloui et al. 2006; Heurteaux et al. 2004;
Noel et al. 2009), we studied the effects of analog treatments
on these potential side effects. We also checked the analog
harmlessness on the two main cardiac repolarizing currents
IKR and IKS that are essential in cardiac function.
Materials and methods
Cell culture
The human-TREK-1/HEK293 cell line (h-TREK-1/HEK)
(Moha ou Maati et al. 2011a) and HEK-IKS cell line (Ducroq
et al. 2010) were grown in the presence of 0.5 mg/mL G418 in
Dulbecco’s modified Eagle’s medium supplemented with 10 %
(v/v) heat-inactivated fetal bovine serum containing 1 % (v/v)
penicillin/streptomycin in an atmosphere of 95 % air/5 % CO2
as previously described (Moha ou Maati et al. 2011a).
HEK-293 native cells were grown in serum in an atmo-
sphere of 95 % air/5 % CO2 in Dulbecco’s modified Eagle’s
medium supplemented with 10 % (v/v) heat-inactivated fetal
bovine containing 1 % (v/v) of penicillin/ streptomycin and
Glutamax X 1. Cells were plated at a density of 20,000 cells/
35 mm dish, and after 24 h, cells were transfected using the Jet
PEI method (Polyplus, France) with 25 ng/35 mm dish of p-
IRES-HERG channel vector. Patch clamp experiments were
carried out 48 h after transfection.
Electrophysiology
All electrophysiological experiments were performed on h-
TREK-1/HEK cells seeded at a density of 20,000 cells/35 mm
dish after 2–6 days of culture. All electrophysiological record-
ings were performed in whole cell configuration of the patch
clamp technique except for IKS measures which were
obtained by using the patch clamp perforated configuration
(amphotericin B 0.9 mg/mL in the pipette medium)
(Moha ou Maati et al. 2011b). Each current was evaluated
by using a RK 400 patch clamp amplifier (Axon Instrument,
USA), low-pass filtered at 3 kHz, and digitized at 10 kHz
using a 12-bit analog-to-digital converter digidata (1322 se-
ries, Axon Instrument, USA). All current amplitudes are
expressed in current densities. Results are expressed as
mean±standard error of the mean (SEM). Patch clamp pi-
pettes were pulled using vertical puller (PC-10, Narishige)
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from borosilicate glass capillaries and had a resistance of 3–
5MΩ. The bath solution contained (in mM) 150 NaCl, 5 KCl,
3 MgCl2, 1 CaCl2, and 10 4-(2-hydroxyethyl)piperazine 1-
ethane sulfonic acid (HEPES) adjusted to pH 7.4 with NaOH.
The pipette solution contained (in mM) 155 KCl, 3 MgCl2, 5
EGTA, and 10 HEPES adjusted to pH 7.2 with KOH. TREK-
1 currents were evaluated at room temperature (21–22 °C) in
the presence of a cocktail of potassium channel inhibitors (K+
blockers, 3 mM 4-aminopyridine (4-AP), 10 mM
tetraethylammonium (TEA), 10 μM glibenclamide, 100 nM
apamin, and 50 nM charybdotoxin). Stimulation protocols
and data acquisition were carried out using a microcomputer
(Dell Pentium) with a commercial software and hardware
(pClamp 8.2). Currents were recorded by voltage clamp steps
to membrane potentials of −100 to +60 mV in 20-mV steps
applied from a holding potential of −80 mV. The duration of
depolarization pulses was 825 ms, and the pulse cycling rate
was 5 s. TREK-1 current amplitudes were evaluated at the end
of stimulation pulses. Cells were continuously superfused
with microperfusion system. TREK-1 inhibitory effects of
spadin or analogs were performed on arachidonic acid pre-
activated currents. Spadin and analogs were tested at the
unique dose of 100 nM on TREK-1 channel activity and at
10 μM on IKR and IKS currents. For both analogs 3 and 8,
TREK-1 concentration-dependent inhibitions were performed
by applying concentrations ranging between 1 nM and 1 μM.
IKS currents were activated by voltage clamp steps of
membrane potentials from −100 to +100 mV in 20-mV steps
applied from a holding potential of −80mV. Tail currents were
generated by repolarization to −40 mV. Duration of both
depolarization and repolarization pulses was 2.4 s, and the
pulse cycling rate was 10 s. IKR currents were activated by
voltage clamp steps of membrane potentials from −100 to +
100 mV in 10-mV steps applied from a holding potential of +
80 mV, and tail currents were generated by a repolarization to
+40 mV. The duration of both depolarization and repolariza-
tion pulses was 1 s, and the pulse cycling rate was 5 s. The
amplitudes of IKS and IKR currents were calculated at both the
end of the first pulse and the peak of the tail pulse.
Animals
Naïve male C57Bl/6J mice from 7 to 9 weeks old were used in
all experiments (Janvier Laboratory, Saint Berthevin, France).
Mice were housed (10 animals per cage) under a 12:12 light–
dark cycle (light on at 8:00 am) in a ventilated room at a
temperature of 22±1 °C. Animals had free access to water and
food (A03; SAFE, Augy, France). All experiments were con-
ducted according to policies on the care and use of laboratory
animals of the Society for Neuroscience and also with respect
to national laws on animal use. The local ethics committee
(CIEPAL) approved the experimental protocols (authorization
number 00736–02).
Treatments
Spadin was synthesized by Gencust (France). Other peptides
(see Fig. 1) were synthesized by the American Peptide
Company (Sunnyvale, CA, USA). Peptides were purified by
the supplier, purity >80 %. The purity was verified by analyt-
ical high-performance liquid chromatography (HPLC) and
mass spectral analysis.
Stock solutions were prepared at 10−3 M in distilled water,
and before injection, spadin or analog solutions were diluted
in NaCl 0.9 % to obtain the different concentrations used for
treatments. Corticosterone (Sigma-Aldrich, France) was dis-
solved in drinking water at the concentration of 3.5 mg/L in
the presence of 4.5 g/L of beta-cyclodextrin. The mixture was
filled into opaque bottles to protect from the light and mice
had a free access to this solution. Fluoxetine (Sigma-Aldrich,
France) was dissolved in drinking water at the dose of 80 mg/
L and administered during 21 days. For i.p. administration,
fluoxetine (TEVA Santé, France) was dissolved in NaCl 0.9 %
at a concentration of 0.75 mg/mL. The total amount injected
was adjusted to obtain 3 mg/kg. Spadin and analogs were
administered by intravenous (i.v.) injection. For acute treat-
ment, drugs were administered in a single 100-μL bolus
30 min prior to the beginning of the behavioral tests. For
subchronic treatment, drugs were injected during four consec-
utive days, and behavioral tests were performed on day 5,
without additional injection.
Behavioral tests
Behavioral experiments were performed with naïve mice. The
experimenter was blind to experimental groups. All mice were
naïve to every behavioral test used.
Fig. 1 Sequences of spadin analogs. Peptide sequences are presented
using the one-letter nomenclature. Amino acids in L-configuration are
shown in capital letters, while amino acids in D-configuration are shown
as lowercase letters. Ac corresponds to acetyl group, −NH2 to amide
group, and spadin and PE correspond to sequences 1 and 11, respectively
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Forced swimming test (FST) (Porsolt et al. 1977)
The animals were individually placed in a non-escapable
cylinder (height 30 cm, diameter 15 cm) filled with 15-cm
water at 22±1 °C. The trial was conducted for 6 min. The total
period of immobility was manually measured during the last
4 min of the test. A mouse was considered immobile when it
remained floating with only slight movements to keep its head
above water.
Novelty suppressed feeding (NSF) (Santarelli et al. 2003)
The NSF paradigm is a 2-day test protocol. On day 1, mice
were deprived from food. On day 2, mice were placed in a
highly brightly lit area, in a plastic box (45×45×20 cm), with
a floor covered with wooden bedding. The test was carried out
during a 10-min period. During this time, the latency to eat
was measured. During the test, a single pellet of food was
placed in the center of the box, on a white platform.
Learned helplessness (LH) (Caldarone et al. 2000)
The learned helplessness test is divided in a 4-day training
session and 1-day test session.
During the training session, mice were exposed to 360
inescapable 2-s footshocks, with an intertrial interval of 8 s.
The test consists in 30 trials separated by a 30-s interval. One
trial was defined as a 5-s period before shock onset and was
terminated when the mouse moved to the second compartment
or at the end of the shock onset. During the test, the latency to
escape for each mouse during every trial was recorded.
Tail immersion test (Alloui et al. 2006)
Mice were i.v. injected with 10 μg/kg of spadin in a bolus of
100 or 100 μL of a saline solution (0.9%NaCl) 30min before
the beginning of the test. The tail was immersed in a water
bath at 48 °C until withdrawal was observed (cutoff time 30 s).
Two separate withdrawal latency time determinations were
averaged (Alloui et al. 2006).
Seizure induced by kaïnate (Tsirka et al. 1995)
Kaïnate solutions were prepared in a solution of 140 mM
NaCl (saline solution).
Spadin 10 μg/kg or vehicle was i.v. injected and, immedi-
ately after the injection, kaïnate, 25 mg/kg, was i.p injected in
a bolus of 100 μL. Mice (n=10 per group) were monitored
during 2 h for onset and extent of seizures. Six levels of
seizure severity were defined: (1) immobility, (2) head/neck
movements, (3) clonic unilateral activity, (4) clonic bilateral
activity, (5) generalized convulsions, and (6) death. Seizure
severity was blindly scored (Tsirka et al. 1995). The seizure
index was calculated by averaging the points for seizure
activity in each group (n=10 per treatment).
Mouse locomotor activity
To determine whether analog 3 induced a change in locomotor
activity, mice (n=8 per group) were injected with the saline
solution or analog 3 (10−5 M in 100 μL bolus, i.v.) 30 min
before starting the test session. Locomotor activity was mon-
itored individually for 24 h using an infrared photobeam
activity monitoring system (Imetronic, Pessac, France), which
measured consecutive horizontal beam breaks. Testing was in
transparent plastic cages (43×20×20 cm3) with fresh bedding
in a grid of 8 cm horizontal infrared beams. Locomotor
activity was defined as breaking of consecutive photobeams.
Movements were recorded and totalized for each 10-min time
section. Six periods were pooled to obtain data for 1 h of time.
Different movements were monitored: the coming-and-going
between the back and the front of the cage, climbing, and
other movements in the back or the front of the cage. Mice
were kept under standard laboratory conditions: 12:12 light–
dark cycle with free access to food and water during the
experiment. Data are the mean value of eight animals per
condition, and bars represent SEM.
Spadin analog recovery in the brain after i.v. injection
Prior to injection, C57BL/6J males were warmed for 5–10 min
with an overhead heat lamp to dilate the veins. Then, they were
placed in a constrained box and injected in the caudal vein with
100 μL of either 100 μM spadin analog 3 or 0.9 % NaCl
solution. The brain was removed either immediately or 30
and 60 min after injection, and the peptide content was recov-
ered by acidic extraction and analyzed by HPLC using a Jasco
apparatus equipped with an analytic RP18 Lichrosorb column
as previously described (Checler et al. 1986). Elutions of HPLC
products were carried out by means of a 50-min linear gradient
of acetonitrile from 10 to 60 % at a flow rate of 1 mL/min.
Under these conditions, the analog was eluted at 31.5 min. The
analog recovered from the brain and identified by mass spec-
trometry was quantified using a standard curve made with
increasing concentrations of analog 3 from 50 to 200 pmol.
Neurogenesis
One day after 5-bromo-2′-deoxyuridine (BrdU) injections,
12 mg per animal divided in four bolus of 300 μL injected
every 2 h, mice were anesthetized with isoflurane and
transcardially perfused with 20 mL of NaCl 0.9 % followed
by 20 mL paraformaldehyde 4 %/NaCl 0.9 %. By using a
vibratome (Leica), brains were cut into 40-μm sections,
throughout the entire hippocampus. Eight slices, from bregma
3.3 to bregma 5.3, were retained to process the BrdU
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immunohistochemistry as previously described (Heurteaux et al.
2006b). For each BrdU labeling, slices were first incubated with
a mouse monoclonal anti-BrdU antibody (1/8,000, Becton
Dickinson). For chromogenic immunodetection, sections were
incubated during 2 h in biotin-conjugated species-specific sec-
ondary antibodies (1/400; Vector laboratories) followed by a
peroxidase-avidin complex solution, to amplify the reaction.
The peroxidase activity of immune complex was visualized with
DAB staining using the VectaStain ABC kit according to the
manufacturer’s protocol (Vector Laboratories).
Statistics
Data were expressed as mean±SEM. Statistical analysis of
differences between groups was performed by using Mann-
Whitney test. In all analyses, the level of significance was set
at p<0.05 (*), p<0.01 (**), and p<0.001 (***).
In the learned helplessness test, latencies to escape were
recorded for each of the 30 trials. The average value was
calculated for each of the five trials; thus, six blocks of values
were obtained in addition to the overall average escape laten-
cy. A Mann-Whitney test was carried out on both overall
latencies and blocks of trials.
Results
Electrophysiological characterization of spadin’s analog
on TREK-1 channel affinity
In order to identify analogs having a better affinity than spadin
for TREK-1 channels, we first studied their ability to
block the channel activity in the h-TREK-1/HEK cell line
(Moha ou Maati et al. 2011a). TREK-1 channels expressed
in this cell line have conserved all their modulating properties
(Moha ou Maati et al. 2011a). By using the whole cell
configuration of the patch clamp technique, analog 2 to analog
12 (Fig. 1) were tested at 100 nM (n=10 to 12) and the analog
1 corresponding to spadin (Mazella et al. 2010; Moha ou
Maati et al. 2011a, b) was used as reference. Our data indicat-
ed that only two analogs, analogs 3 and 8, presented an
increased blockade effect when compared to spadin
(Fig. 2a, b). Analog 2 that corresponds to the N-terminal-
acetylated and C-terminal amidated form of spadin displayed
similar activity to spadin. IC50 values calculated from dose–
response curves were of 11.5±0.59 and 9.95±0.85 nM for
analogs 3 and 8, respectively (Fig. 2c). These values had to be
compared to 56.39±0.01 nM determined for spadin on the
same cell line (Moha ou Maati et al. 2011a), noting that
analog 2 had an IC50 of 60±0.41 nM (Fig. 2c). These
data indicated that both analogs 3 and 8 have a sixfold
higher affinity for TREK-1 channels. We retained these
analogs in order to investigate their potential antidepres-
sant properties.
Antidepressant effect of spadin’s analogs after an acute
treatment
Because the FST is based on the immobility and influenced by
molecules that spontaneously increase the general activity, we
controlled the effect of analogs on mouse locomotion. By
using an infrared photobeam activity monitoring system, we
showed that there was no significant difference in locomotor
activities between analog 3- and saline-treated mice within
24 h after the drug injection (Fig. 3). Coming-and-going
(Fig. 3a), climbing (Fig. 3b), and total movements (Fig. 3c)
were very similar in both conditions. These results indicate
that the difference in the immobility time we further observed
in the FSTwas really due to the effect of the analog treatment
and not to a change in the locomotor activity.
The antidepressant effects of both analogs were first stud-
ied in the FST after an acute injection (Mazella et al. 2010).
Here again, spadin was used as control. A 10-μg/kg acute i.v.
injection of spadin or both analogs 3 and 8 significantly
reduced the immobility time of mice compared to saline-
injected mice (Fig. 4a). Values were 166.13±5.54, 107.40±
5.05, 135.10±8.11, and 83.60±9.01 s for saline, spadin (U=0,
p<0.001), analog 3 (U=8, p=0.01), and analog 8 (U=0, p=
0.001), respectively (n=10 for each group).
Antidepressant effect of spadin’s analogs after a subchronic
treatment
The main goal of this study was to find a molecule that can be
used in clinic. Thus, we needed a molecule that remained active
after several days of administration. Consequently, as already
performed with spadin (Mazella et al. 2010), we pursued our
study after a subchronic administration of both analogs.
In the FST, subchronic treatments of 4 days (10 μg/kg i.v.
injected once a day) with spadin or analogs induced a signif-
icant decrease of immobility times. Immobility times ob-
served were of 161.80±8.12 s, 123.70±7.16 s (U=10.5,
p<0.01), 114.9±9.82 s (U=10.5, p<0.01), and 124.1±
10.53 s (U=17.5, p<0.05) for saline solution, spadin, analog
3, and analog 8, respectively (Fig. 4b).
Similar results were obtained in the novelty suppressed
feeding test. Spadin and both analogs reduced the latency to
feed. Values were of 305.00±62.47 s, 151.11±17.70 s (U=13,
p<0.05), 143.88±23.42 s (U=11, p<0.05), and 167.00±
22.96 s (U=13, p<0.05) for saline solution, spadin, analog
3, and analog 8, respectively (Fig. 4c). Although weaker, this
antidepressant effect was also observed with learned helpless-
ness test (LHT) (Fig. 4d, e).
Our data clearly indicated that, as spadin, analogs are
efficient after only 4 days of treatment.
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Analog stability
For improving the spadin efficacy, in addition to an increased
affinity, analogs have to be more stable when injected in vivo.
Measured with the FST, the efficacy of spadin decreased from
100 % at t=1 h after the injection to 0 % at t=16 h, with
intermediate values of 84 % at t=3 h and 30 % at t=7 h
(Fig. 5a). Times of immobility were of 170.3±4.5 s, 102.4±
6.2 s (U=0, p<0.001), 113.2±5.0 s (U=0, p<0.001), 150.8±
6.5 s (U=19, p<0.05), and 175.3±7.5 s (Fig. 5a). These
data indicated that the biological half-life time of spadin
is around 6 h.
Fig. 2 I–V curves of spadin and its analogs. All experiments were
performed on h-TREK-1/HEK cell line in the presence of a mixture of
K+ channels blockers and by using the whole cell configuration of the
patch clamp technique. a Control currents (black-filled circles, K+
blockers) were amplified by the application of 10 μM of arachidonic acid
(white-filled circles, K+ blockers + AA). After application of 100 nM of
spadin or its analogs, remaining currents were measured (black-filled
triangles, K+ blockers + AA + spadin or analog). b Percentage of
inhibition of the TREK-1 current measured at 0 mVobtained by applica-
tion of 100 nM of spadin and different analogs. c Dose–response curves
obtained by measuring the percentage of TREK-1 current inhibition at
0 mV with analog 2 (white-filled circles), analog 3 (black-filled circles),
and analog 8 (black-filled squares)
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Then, analogs 3 and 8 were tested at different times, 1, 3, 7,
12, 16, 18, 20, and 24 h, after the injection (n=10 naïve mice
at each time). Saline-injected animals were only tested at 1 and
24 h (Fig. 5b). It appeared that both analogs remained efficient
to reduce the immobility time after 16 h. The immobility times
were very similar between 1 and 16 h, 123.4±7.0 and 129.6±
12.7 s, and 121.7±5.2 and 129.1±12.0 s for analog 3 and
analog 8, respectively (Fig. 5b). The mean value for saline-
treated animals was of 162.7±4.7 s (Fig. 5b).
In the aim to determine the ability of analogs to cross the
blood–brain-barrier, we used analog 3 as the model. Of analog
3, 10 nmol was intravenously injected, and the amount recov-
ered in the brain was estimated by HPLC analysis (Fig. 6). In
the peptide content analyzed from a half brain extract after
30 min of injection, a peak not present in the basal condition
(0 min; Fig. 6a) was observed with a retention time of
31.5 min (Fig. 6b). This peak disappeared after 60 min
(Fig. 6c). This peak was identified as analog 3 by its retention
time identical to standards directly analyzed by HPLC
(Fig. 6d) and by mass spectrometry. From different amounts
detected by HPLC (Fig. 6d), we determined the amount of
analog 3 recovered in the brain (Fig. 6e, arrow) which was
estimated to be 100 pmol for a half brain then to be 200 pmol
per brain. Therefore, we can estimate to 2 % the yield of
analog 3 to cross the blood–brain-barrier. This value corre-
sponds to an increase by a factor 20 of the percentage esti-
mated for spadin (Mazella et al. 2010).
These data clearly indicated that both analogs have better
in vivo action duration than spadin itself.
Effects of analogs on neurogenesis
It was previously shown that a 4-day subchronic treatment
with spadin increased the hippocampal neurogenesis (Mazella
et al. 2010). We investigated the ability of both analogs to
induce a neoneurogenesis in the subgranular zone (SGZ) of
the hippocampal dentate gyrus, by counting the number of
progenitor cells that incorporated the DNA synthesis marker
BrdU. In SGZ, a 4-day treatment with spadin or analogs
significantly increased the number of BrdU-positive cells by
Fig. 3 Spontaneous locomotor
activity of analog 3-injected mice.
Mice were injected 30 min before




individually for 24 consecutive
hours. The number of coming-
and-going (a), climbing (b), and
total movements except climbing
(c) were monitored for each
mouse for 10 min section and
pooled by 6 to obtain values
corresponding to 1 h. Light and
dark periods are indicated by the
bar above profiles
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at least a factor 2 when compared to saline conditions
(Fig. 7a, b).
These data indicated that both analogs are able to induce
neurogenesis.
Potential side effects on -TREK-1controlled functions
Because TREK-1 channels are being involved in pain, we
analyzed the effects of both analogs 3 and 8 on thermal
pain by using the tail immersion test. It clearly appeared
that both analogs as well as spadin did not increase the
thermal pain sensation (Fig. 8a). Measured tail with-
drawal times were of 12.75±0.96, 11.79±0.89, 11.32±
1.04, and 13.85±0.72 s for saline, spadin, analog 3, and
analog 8, respectively (Fig. 8a).
Because both analogs displayed the same properties and
the same efficacy in behavioral tests, we decided to focalize on
analog 3. This choice was supported by the fact that analog 3
is the retro-inverso of spadin and consequently shorter than
analog 8. Moreover, analog 3 appeared more stable in its
in vivo efficacy (see Fig. 5b) than analog 8.
TREK-1 channel deletion is known to induce epilepsy
(Heurteaux et al. 2004). We analyzed the effects of analog 3,
a potent blocker of TREK-1, on seizures triggered by kaïnate
injection (Fig. 8b). Surprisingly, we observed that analog 3 at
a dose of 10 μg/kg i.v. injected had an important protective
effect against epilepsy seizures triggered by kaïnate injections
(25 mg/kg in a bolus of 100 μL). Only two mice among 10
injected with both kaïnate and analog 3 have reached the two
less severe stages of the epilepsy seizures, immobility, and
Fig. 4 Behavioral tests with spadin and analogs 3 and 8. a FST per-
formed after an acute treatment, immobility times were measured 30 min
after the i.v. injection of drugs, 10 μg/kg in a single bolus of 100 μL of
NaCl 0.9 %. b FST performed after a subchronic treatment (4 days, 4d);
immobility times were measured on the fifth day after a daily i.v. injection
of drugs, 10 μg/kg in a single bolus of 100 μL of NaCl 0.9 % for four
consecutive days. c NSF performed after a subchronic treatment (4 days,
4d); latencies to feed were measured on the fifth day after a daily i.v.
injection of drugs, 10μg/kg in a single bolus of 100 μL of NaCl 0.9 % for
4 days. d, e LHT performed after a subchronic treatment (4 days, 4d);
latencies to feed were measured on the fifth day after a daily i.v. injection
of drugs, 10μg/kg in a single bolus of 100 μL of NaCl 0.9% for 4 days. d
Mean escape latencies for the entire experiment. e The mean escape
latencies by blocks of five trials. *p<0.05, **p<0.01, ***p<0.001
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head or neck movements; no other stages of epilepsy were
observed for analog 3-treated mice. At least 9 among 10
saline-injected mice have reached the two first stages and five
of them died (Fig. 8b). The effect of analog 3 was dose-
dependent since a dose of 1 μg/kg showed no protective effect
(Fig. 8b).
Potential side effects on cardiac repolarizing currents
It was also important to check that analog 3 as spadin is
without effects on the two main repolarizing currents at the
cardiac level, the fast component IKR and the slow component
IKS. These channels are important because they are responsi-
ble for the torsades de pointe which can lead to the death. One
of the most important side effects of antidepressant molecules
is to induce torsades de pointe. Analog 3 did not modify
currents generated either by IKR or IKS channels expressed in
HEK cells (Fig. 8c, d).
The current densities measured for IKR at 0 mVat the end of
first pulse were 225.14±33.09 pA/pF (n=5) and 224.48±
35.94 pA/pF (n=5) in the absence or the presence of analog
3, respectively (Fig. 8c). At the same potential, tail current
densities in the absence or in the presence of analog 3 were
204.59±34.18 pA/pF (n=5) and 212.99±38.38 pA/pF (n=5),
respectively (Fig. 8c). IKS current densities measured at 0 mV
were also very close. At the end of pulses, these values were of
17.65±3.84 pA/pF (n=5) and 17.58±4.03 pA/pF (n=5) in the
absence or the presence of analog 3, respectively (Fig. 8d). IKS
tail current densities were of 8.33±1.78 pA/pF (n=5) and 8.33
±2.06 pA/pF (n=5), in the absence or in the presence of
analog 3, respectively (Fig. 8d).
Chronic treatment
To study the effects of a chronic treatment with analog 3, we
used the same strategy that we used for spadin, the MedinGel
formulation (Moha ou Maati et al. 2011b). Due to fact that a
single subcutaneous injection is sufficient to obtain a constant
and continuous controlled release of the active molecule for
several weeks, this formulation offered the advantage to re-
duce the stress due to a daily injection.
Formulations were prepared in a way to obtain a release of
10 μg/kg/day of peptide when injected.
The efficacy of analog 3 was measured by FST after 1, 2,
and 4 weeks. At each time, tested mice are naïve for the test.
Mice treated with the analog 3 formulation showed a signif-
icant reduction of immobility times (Fig. 9). After 1 week, the
immobility times measured were 134.40±10.45 vs 112.00±
9.31 s (U=21.5, p<0.05) for the placebo-injected and analog
3 formulation-injected mice, respectively. After 2 weeks, the
immobility values were 133.80±11.03 vs 99.60±4.92 s (U=
17.5, p<0.05) for the placebo-injected and analog 3
formulation-injected mice, respectively. Interestingly, an-
alog 3 released by the MedinGel formulation was still
active after 4 weeks, and the corresponding values are
of 137.20±6.93 vs 101.10±14.05 s (U=20, p<0.05) for
the placebo-injected and analog 3 formulation-injected
mice, respectively.
Fig. 5 In vivo stability of spadin
and analogs 3 and 8. Using FST,
we compared the in vivo action
duration of spadin (a) with both
analogs 3 and 8 (b). For each drug
at each, times animals were naïve.
*p<0.05, **p<0.01,
***p<0.001, ns nonspecific
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Fig. 6 Analog 3 crosses the
blood–brain-barrier. a–c HPLC
profiles of analog 3 recovered in
the brain at 0 min (a), 30 min (b),
and 60 min (c) after i.v. injection.
The brain was subjected to acidic
extraction, and the extracted
peptide content was analyzed by
reverse-phase HPLC. The
retention time for analog 3 is
indicated by the arrow (31.5min).
d, e 50, 100, and 200 pmol of
analog 3 were directly quantified
by HPLC (d) and the linear
representation of the OD obtained
as a function of the amount of
peptide (e) allowed us to
determine the amount of analog 3
recovered in the brain extract
(arrow)
Fig. 7 Neurogenesis. a Representative photomicrographs of BrdU-
labeled neurons in the dentate gyrus of the mouse hippocampus treated
for 4 days either with saline, spadin, analog 3, or analog 8 (i.v., 10 μg/kg
for all drugs). Arrows showed examples of positive cells. b Quantitation
of BrdU-positive cells of hippocampus treated with saline, spadin, analog
3, or analog 8 for four consecutive days by an i.v. injection of drugs at
10 μg/kg in a single bolus of 100 μL of NaCl 0.9 %. *p<0.05, **p<0.01
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Discussion
Spadin was recently identified as a new antidepressant in
rodent models (Mazella et al. 2010). In this study, we identi-
fied two more efficient spadin-derived analogs. The main
features of spadin as antidepressant are its rapid onset of action
(4 days instead of 21 days) (Mazella et al. 2010) and the
absence of side effects (Moha ou Maati et al. 2011b).
Nevertheless, in vivo Spadin half-life time measured by the
FSTwas relatively short, around 6 h (Fig. 4). With the aim to
decrease the drug intake, we decided to screen spadin analogs
showing both an increased affinity for the target TREK-1
channels, which were previously identified as the target for
spadin, and an increased bioavailability.
For designing these analogs, we decided to test, among
others (Fig. 1), the retro-inverso (RI) peptides. For more than
20 years, it has been shown that these peptides retain their
bioactivity (Chorev and Goodman 1995) and often such RI
peptides display an increased bioactivity (Chorev and
Goodman 1995; Taylor et al. 2000; Taylor et al. 2010). The
Fig. 8 Side effects. a Tail flick test (n=10 per group). For each mouse,
the time to withdraw its tail immersed in a water bath at 48 °C was
measured twice and averaged. There was no significant difference be-
tween saline, spadin, or analog 3-treated mice. b Epilepsy. Seizures were
triggered by an i.p. injection of kaïnate (25 mg/kg) that was immediately
followed an i.v. injection of saline solution or analog 3 at 1 or 10μg/kg in
100 μL bolus (n=10 per group). The number of animals reaching the
different levels of severity was counted. c, dAnalog 3 (10 μM) effects on
the cardiac delayed K+ rectifying currents IKR and IKS. c Typical traces of
human whole cell hERG current recordings in the absence (control) (a) or
in the presence of 10 μM analog 3 (b). c, d I/V curves obtained with the
first pulse (c, end of pulse) and the second pulse (d, tail current) of hERG
current (n=5). d Typical traces of human whole cell human-IKS current
recordings in the absence (control) (a) or in the presence of 10 μM analog
3 (b). c, d I/V curves obtained with the first pulse (c, end of pulse) and the
second pulse (d, tail current) of human-IKS current (n=5)
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fact that RI peptides can cross the BBB was already demon-
strated for peptides involved in apoptosis of cerebral granules
(Taylor et al. 2000) or for mu-opioid receptor ligands (Dooley
et al. 1994).
Electrophysiology and spadin analog screening
Among 11 analogs of spadin, the most efficient TREK-1
channel inhibition was observed with two RI analogs, analogs
3 and 8. It appeared that shorter analogs, analog 4 to 6,
displayed a very low inhibition efficacy, less than 30 % when
compared to the maximal inhibition. Intriguingly, analog 7
was also a bad inhibitor of TREK-1 channels, while it corre-
sponds to the L-amino acid sequence of the analog 8 which is
one of the two most potent TREK-1 channel inhibitors. It only
differs by five amino acids (QDRLD) from analog 9 that
displayed an inhibitory effect close to that of spadin. The
importance of these amino acids in the absence of effect is
partly reversed by longer peptides (see analogs 11 and 12).
Analog 11 corresponds to the 44 amino acid PE released by
the furin in the Golgi vesicle (Munck Petersen et al. 1999). Its
reduced blocking effect on TREK-1 channels was already
described (Mazella et al. 2010) but, conversely to spadin its
RI-analog, analog 12 did not display a better efficacy. In
summary, it appeared that better efficacies were found with
RI analogs bearing the full spadin sequence such as analogs 3
and 8. Dose–response curves indicated that analog affinities
were increased by a factor 5 for analog 3 and a factor 6 for
analog 8. These results have allowed us to pursue the
investigation with these molecules for pointing out their
potential antidepressant properties and their absence of
side effects on functions that are controlled by the
TREK-1 channel like pain and epilepsy. We also ana-
lyzed their action on the cardiac function by measuring
their effects on the two main repolarizing potassium
channels in the heart.
Spadin analogs, antidepressant effects, and neurogenesis
Both analogs 3 and 8 showed the same antidepressant prop-
erties as spadin in several behavioral tests after acute or
subchronic treatments. In the FST, after an acute injection or
a 4-day treatment, spadin and both analogs behaved similarly.
We demonstrated that the decrease in the immobility time was
not due to an excitatory effect of analogs since the spontane-
ous locomotor activity was similar for saline-or analog-
injected mice. Analog-injected mice showed an important
reduction of the latency to feed in the novelty suppressed
feeding test. This test was described to be related with
neoneurogenesis in the hippocampus area, a process induced
by Alzheimer’s disease treatments (Malberg and Schechter
2005; Santarelli et al. 2003). Indeed as spadin did, both
analogs increased the number of labelled BrdU neurons in
the mouse hippocampus. We have previously shown that
80 % of BrdU-positive neurons were also double cortin pos-
itive indicating that the fate of these cells was to become
neurons (Mazella et al. 2010). Our data indicated that RI-
spadin analogs are not only able to bind on the spadin target
the TREK-1 channel but also to trigger antidepressant spadin-
like effects.
Spadin analogs and in vivo stability
Interestingly and as expected, these analogs presented an
increased in vivo action duration. Measured by the FST, their
antidepressant properties were still present 16 h after the
injection. This time is about three times longer than this
observed for spadin (6 h). In parallel, we showed that analog
3 is able to cross the blood–brain barrier since 30 min after the
injection, a peak with a retention time corresponding to analog
3 was recovered in brain extracts. Mass spectroscopy analysis
confirmed that this peak was analog 3. This peak is absent at
t=0, and it has completely disappeared at t=60 min. The fact
that the antidepressant effect of analog 3 was still measurable
16 h after injection whereas it was no more observable in the
brain after 1 h could be accounted by at least two hypotheses.
First, the effect is a longlasting effect and the difference
between spadin and its analog could be due to the amount
that reached the brain (20 times more with analog). Second,
after several hours, the level of analog is too weak to be
identified by HPLC analysis. A combination of both hypoth-
eses cannot be excluded. Our data confirmed that bioactive
retro-inverso peptides presented an increased bioactivity in
comparison to the native structure (Chorev and Goodman
1995; Taylor et al. 2000).
Spadin analogs and side effects
Since both analogs have the same binding and antidepressant
properties, analog 3 presented the best activity/cost
Fig. 9 Effects of long-term treatments with spadin. Spadin–MedinGel
formulation and placebo–MedinGel were subcutaneously injected in the
neck of mice. Immobility times were measured in FST at 1, 2, or 4 weeks
(W1, W2, W4) after injection. For each week, values obtained with
formulations were compared with their corresponding placebo values
by using the Mann-Whitney test. PLB, placebo, *p<0.05
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compromise and was investigated for potential side effects.
Treatingmice with analog 3 did not increase their thermal pain
sensitivity, confirming data obtained with spadin (Moha ou
Maati et al. 2011b). Interestingly, on kaïnate-triggered epilep-
tic seizures, analog 3 at a dose of 1 μg/kg had no effect on the
severity of seizures. But when administrated at a dose of
10 μg/kg, analog 3 showed a high degree of protection against
seizures. At this dose, only two animals reached the two first
level of seizure severity while nine saline-injected mice
reached these levels. Treating animals with analog 3 amplified
the protective effect against seizures which was glimpsed with
spadin (Moha ou Maati et al. 2011b). As many drugs can
induce cardiac dysfunction, among them ADs (Downes et al.
2005; Heist and Ruskin 2005), we analyzed analog 3 effects on
IKR and IKS currents, the twomain potassium channels at cardiac
level, that are responsible for torsades de pointe and sudden
death (Aizawa et al. 2007; Fenichel et al. 2004; Schechter et al.
2005). Analog 3 was without effects on both currents. As in the
case of spadin (Moha ou Maati et al. 2011b), these results
demonstrated that RI analogs of spadin did not interfere with
other TREK-1-controlled pathways and did not modify the
cardiac function.
Spadin analogs and chronic treatment
Analog 3 was also used to verify that the antidepressant effect
was persistent even after a chronic treatment. This experiment
was performed, thanks to a MedinGel formulation that allows
following a single subcutaneous injection a continuous con-
trolled release of the peptide during several weeks (Moha ou
Maati et al. 2011b). Data showed that the antidepressant effect
was the same after 4 weeks and demonstrated that there was
no tolerance.
Conclusion
The three fold increase in the bioavailability associated with
five- or sixfold increase in the affinity of RI-peptide for the
TREK-1 channel indicated that analogs improved by a factor
15 to 18 the efficacy of spadin. Additionally, RI analogs did
not induce side effects and their action was stable over the
time. Taken together, these properties are very important in the
aim to transform spadin or its analogs into a usable drug in
human clinic. Indeed, one third of patients remain un-
treated because they do not correctly take their drugs.
Improvements to simplify drug intake will be very help-
ful for these patients. In this study, we have identified a
very potent spadin analog that, associated with a
MedinGel formulation, could represent a great step in
the spadin drug design concept for treating these un-
treated patients.
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